Cargando…
Folfirinox versus gemcitabine-cisplatin combination as first-line therapy in treatment of pancreaticobiliary cancer
BACKGROUND/AIM: The purpose of this study was to compare efficacy and safety of a combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) and gemcitabine-cisplatin as first-line therapy in patients with pancreatic cancer. MATERIALS AND METHO...
Autores principales: | KAYAHAN, Neslihan, KARACA, Mustafa, SATIŞ, Hasan, YAPAR, Dilek, ÖZET, Ahmet |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Scientific and Technological Research Council of Turkey
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8569782/ https://www.ncbi.nlm.nih.gov/pubmed/33315355 http://dx.doi.org/10.3906/sag-2009-115 |
Ejemplares similares
-
Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine
por: Di Costanzo, Francesco, et al.
Publicado: (2023) -
Predictors of two-year mortality in patients with dementia with Lewy bodies
por: KAYAHAN SATIŞ, Neslihan, et al.
Publicado: (2022) -
Folfirinox versus gemcitabine/nab-paclitaxel as
first-line therapy in patients with metastatic pancreatic cancer: a comparative
propensity score study
por: Williet, Nicolas, et al.
Publicado: (2019) -
Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
por: Vogl, Ursula M., et al.
Publicado: (2019) -
Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
por: Klein-Brill, Avital, et al.
Publicado: (2022)